Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis
Journal of Allergy and Clinical Immunology · 2025
DOI: 10.1016/j.jaci.2024.08.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025. Verfasst von Lisa A Beck und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Rochester Medical Center, Rochester, NY. Electronic address: lisa_beck@urmc.rochester.edu. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Biomarkers, Chemokine CCL17, Dermatitis, Atopic. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Patients with atopic dermatitis (AD) often have elevated type 2 inflammatory serum biomarkers. OBJECTIVE: The aim was to report changes in thymus and activation-regulated chemokine (TARC)/CC chemokine ligand 17 (CCL17), total IgE, lactate dehydrogenase (LDH), and eosinophils in pediatric patients treated with dupilumab or placebo. METHODS: Biomarker data were analyzed from 3 randomized, double-blind, placebo-controlled, phase 3 studies of patients with moderate-to-severe AD. Patients ages 6 months to 5 years were randomly assigned to weight-dependent dupilumab 200/300 mg every 4 weeks (q4w) or placebo; ages 6 to 11 years, to dupilumab 100/200 mg every 2 weeks (q2w), dupilumab 300 mg q4w, or placebo; ages 12 to 17 years, to dupilumab 200/300 mg q2w, dupilumab 300 mg q4w, or placebo. In the youngest 2 groups, topical corticosteroids were also applied. Median percent changes from baseline to week 16 were reported using last observation carried forward analysis, censoring after rescue treatment. RESULTS: Pediatric patients who received dupilumab versus placebo achieved significantly greater median percent reductions at week 16 in TARC/CCL17 (-83.3% to -72.4% vs -14.9% to -1.8%), total IgE (-71.2% to -58.4% vs -21.0% to +28.1%), and LDH (-26.2% to -9.8% vs -1.5% to +1.5%). All comparisons were significantly different (P < .0001) between each dupilumab dosing group and respective placebo groups. In contrast, absolute changes in eosinophils were small in all groups. CONCLUSIONS: Dupilumab treatment for pediatric patients with moderate-to-severe AD significantly reduced levels of TARC/CCL17, total IgE, and LDH to levels comparable with those of healthy controls, reflecting a reduction in systemic type 2 and general inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Rochester Medical Center, Rochester, NY. Electronic address: lisa_beck@urmc.rochester.edu.
- Food Allergy Referral Centre, Padua University Hospital, Padua, Italy.
- Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health, Denver, Colo; University of Colorado School of Medicine, Denver, Colo.
- Regeneron Pharmaceuticals Inc, Tarrytown, NY.
- Sanofi, Madrid, Spain.
Zitieren
APA
Beck, L. A., Muraro, A., Boguniewicz, M., Chen, Z., Zahn, J., & Rodríguez Marco, A. (2025). Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2024.08.005
Vancouver
Beck LA, Muraro A, Boguniewicz M, Chen Z, Zahn J, Rodríguez Marco A. Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis. Journal of Allergy and Clinical Immunology. 2025. doi:10.1016/j.jaci.2024.08.005
BibTeX
@article{Beck2025,
author = {Beck, Lisa A and Muraro, Antonella and Boguniewicz, Mark and Chen, Zhen and Zahn, Joseph and Rodríguez Marco, Ainara},
title = {Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
doi = {10.1016/j.jaci.2024.08.005}
}
EUVIMED